文献速递肝病

体重变化对MASLD的影响因遗传与代谢风险而异

Weight changes differentially impact MASLD incidence, progression and outcomes based on genetic and metabolic risk profiles.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-10-09

基于英国生物银行队列,研究评估体重动态对不同遗传与代谢风险分组人群的MASLD发病、缓解及心血管结局的影响。结果显示每减重1%与MASLD风险降低10%、缓解率升高9%相关,且不同风险组推荐的减重阈值不同。

要点

  • 每减重1%与MASLD发病风险降低10%相关(HR=0.90)。
  • 每减重1%与MASLD缓解率升高9%相关(HR=1.09)。
  • 不同遗传与代谢风险组推荐的预防与缓解减重阈值存在差异。

核心结论

  • 应根据个体的遗传与代谢风险特征推荐个体化体重管理。

研究设计与样本

  • 基于英国生物银行队列,评估体重动态对MASLD发病、脂肪变缓解、纤维化风险逆转及相关心血管疾病的影响。
  • 遗传亚组(肝脏型和全身型)由多基因风险评分定义,代谢风险组由脂质蓄积产物定义。
  • 采用Cox比例风险模型在一般人群及按性别分层亚组中评估影响。

主要发现

  • 在11,882名无MASLD参与者中,中位随访4年期间1,350人发生MASLD。
  • 体重每降低1%与MASLD风险降低10%相关(HR=0.90 [0.89-0.91])。
  • 在6,013名MASLD参与者中,753人实现MASLD缓解;体重每降低1%与缓解率升高9%相关(HR=1.09 [1.08-1.10])。
  • 体重减轻还与MASLD相关心血管疾病风险降低相关(HR=0.98 [0.97-0.99])。

关键数值与推荐

  • MASLD预防推荐减重幅度(男/女):肝脏风险组8.7%/13.1%,全身风险组8.0%/11.8%,代谢风险组10.9%/14.4%。
  • 与MASLD缓解相关的估计较低减重阈值(男/女):肝脏风险组5.3%/13.3%,全身风险组10.2%/10.7%,代谢风险组5.7%/5.8%。
  • 纤维化风险逆转:肝脏风险组未识别出稳健阈值,代谢风险组为7.7%/5.6%(男/女)。

临床怎么用

  • 临床应根据患者的遗传与代谢风险分组设定个体化减重目标以预防或缓解MASLD。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) comprises heterogeneous subgroups with liver- vs. cardiovascular-related adverse outcomes. Weight management is crucial in MASLD prevention and treatment, but its effect on MASLD subgroups is unclear. METHODS: We assessed the impact of body weight dynamics on incident MASLD, steatosis resolution, fibrosis risk regression and related cardiovascular diseases (CVD) from the UK biobank. Genetic subgroups (i.e., hepatic and systemic) were defined by polygenic risk scores, a metabolic risk group by lipid accumulation product. A Cox proportional model evaluated impacts across the general population and sex-stratified subgroups. RESULTS: Among 11,882 participants without MASLD, 1,350 developed MASLD during a median follow-up of 4 years. Each 1% reduction in body weight was associated with a 10% lower risk of MASLD (HR = 0.90 [0.89-0.91]). Among 6,013 participants with MASLD, 753 achieved MASLD resolution; each 1% weight reduction was associated with a 9% higher rate of resolution (HR = 1.09 [1.08-1.10]). Weight loss was also associated with a lower risk of MASLD-related CVD (HR = 0.98 [0.97-0.99]). Recommended weight loss for MASLD prevention (male/female) differed across hepatic (8.7%/13.1%), systemic (8.0%/11.8%), and metabolic-risk (10.9%/14.4%) groups. Estimated lower weight-loss thresholds associated with MASLD resolution were 5.3%/13.3% in hepatic-risk, 10.2%/10.7% in systemic-risk, and 5.7%/5.8% in metabolic-risk participants (male/female). For fibrosis-risk regression, no robust threshold was identified in hepatic-risk participants, but 7.7%/5.6% in metabolic-risk participants (male/female). CONCLUSION: Individualized weight management should be recommended according to the genetic and metabolic risk profiles of individuals.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Chen L, Chieh Kow AW, Lv G, et al. Weight changes differentially impact MASLD incidence, progression and outcomes based on genetic and metabolic risk profiles. Clin Gastroenterol Hepatol. 2026. PMID: 42854771. doi:10.1016/j.cgh.2026.07.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。